Regulatory, Legislative Changes Would Spur Preventative Research – Lilly
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA should give guidance about approval requirements and promotion of preventative treatments, Lilly exec Stotka says during conference call on barriers to cancer prevention research. Higher R&D costs, slower review times and shorter periods of exclusivity also cited as impediments to developing preventative agents.